Literature DB >> 11198954

Prostate-specific antigen: current status.

M K Brawer1.   

Abstract

Prostate-specific antigen (PSA) is the most important of all tumor markers in that it has significant applications in all aspects of the management of men with prostatic disease. Certainly, the most important utilization of PSA is for the early detection of this most ubiquitous of all human neoplasms. This article reviews the salient features of PSA, with particular emphasis on strategies to improve its utility in the diagnosis of prostate cancer. So-called PSA derivatives--including age-specific PSA, PSA velocity, and PSA density--are discussed. With the recognition of molecular forms of PSA, however, the ratio of free-to-total PSA, and now the complex form of PSA, have been shown to be more specific indicators of the presence of malignancy. Significant public interest and research efforts in prostate cancer have resulted in numerous advances over the past decade. The discovery of PSA and the development of assays to measure it will undoubtedly be recorded as one of the most important advances in the management of men with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11198954     DOI: 10.3322/canjclin.49.5.264

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  36 in total

1.  Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.

Authors:  Dennis J O'Rourke; Daniel A DiJohnson; Robert J Caiazzo; James C Nelson; David Ure; Michael P O'Leary; Jerome P Richie; Brian C-S Liu
Journal:  Clin Chim Acta       Date:  2011-11-29       Impact factor: 3.786

Review 2.  Biochemical individuality reflected in chromatographic, electrophoretic and mass-spectrometric profiles.

Authors:  Milos V Novotny; Helena A Soini; Yehia Mechref
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-04-15       Impact factor: 3.205

Review 3.  Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening.

Authors:  Ashwin A Kotwal; Mara A Schonberg
Journal:  Cancer J       Date:  2017 Jul/Aug       Impact factor: 3.360

Review 4.  Prostate cancer.

Authors:  D Mazhar; J Waxman
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 5.  Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Authors:  Eva-Margarete Spur; Emily A Decelle; Leo L Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-03       Impact factor: 9.236

Review 6.  Identifying cancer biomarkers by mass spectrometry-based glycomics.

Authors:  Yehia Mechref; Yunli Hu; Aldo Garcia; Ahmed Hussein
Journal:  Electrophoresis       Date:  2012-07       Impact factor: 3.535

7.  Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.

Authors:  Danni L Meany; Lori J Sokoll; Daniel W Chan
Journal:  Expert Opin Med Diagn       Date:  2009-11-01

8.  Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test.

Authors:  Pamela A Shaw; Margaret S Pepe; Todd A Alonzo; Ruth Etzioni
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

9.  External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.

Authors:  Hans Reinauer; William Graham Wood
Journal:  Ger Med Sci       Date:  2005-05-30

10.  The routine use of prostate-specific antigen for early detection of cancer prostate in India: Is it justified?

Authors:  Deepak Dubey
Journal:  Indian J Urol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.